Genotyping of AAV Plasmid Stocks: Quality Control in Adeno-Associated Virus Vector Production

被引:2
作者
Schmitt, Markus [1 ]
Pawlita, Michael [1 ]
Kleinschmidt, Juergen [1 ]
机构
[1] German Canc Res Ctr, Res Program Infect & Canc, DE-69120 Heidelberg, Germany
关键词
Adeno-associated virus vector production; Gene therapy; Quality control; Multiplex AAV genotyping; HUMAN GENE-THERAPY; INSERTIONAL MUTAGENESIS; PARKINSONS-DISEASE; VIRAL VECTORS; HELPER VIRUS; CAPSID GENE; FACTOR-IX; SEROTYPES; GENERATION; LIVER;
D O I
10.1159/000321449
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Recombinant adeno-associated virus (rAAV) vectors are a promising tool for gene therapy. When multiple serotypes are handled in the same laboratory during the AAV vector production, it is essential to have means to identify the serotype in a sample and to confirm the absence of cross-contaminating AAV sequences in plasmid stocks as well as end products. Here, we describe the development of a Multiplex AAV Genotyping (MAG) assay to type sensitively and specifically DNA from AAV serotypes 1-12 and to detect AAV2 serotype DNA sequences encoding peptide insertions used to modify tissue tropism. MAG is based on multiplex PCR using type-specific primers and subsequent multiplex hybridization by Luminex. The assay is highly specific, and can easily identify plasmid cross-contaminations. Using 10-fold dilution series, the detection limit was below 10 AAV genomes per PCR. In artificial cross-contamination experiments with a 1,000-fold excess of one AAV serotype versus another one, the contaminating type could be still detected with 10-100 AAV genomes. In a first application, MAG identified successfully cross-contaminated AAV plasmid stocks. In conclusion, MAG is a powerful high-throughput tool in assessing the purity and identity of AAV DNA plasmids and other starting materials used for AAV vector production. Copyright (C) 2010 S. Karger AG, Basel
引用
收藏
页码:204 / 212
页数:9
相关论文
共 36 条
[1]   AAV hybrid serotypes: Improved vectors for gene delivery [J].
Choi, VW ;
McCarty, DM ;
Samulski, RJ .
CURRENT GENE THERAPY, 2005, 5 (03) :299-310
[2]  
Conrad CK, 1996, GENE THER, V3, P658
[3]   In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector [J].
During, MJ ;
Samulski, RJ ;
Elsworth, JD ;
Kaplitt, MG ;
Leone, P ;
Xiao, X ;
Li, J ;
Freese, A ;
Taylor, JR ;
Roth, RH ;
Sladek, JR ;
O'Malley, KL ;
Redmond, DE .
GENE THERAPY, 1998, 5 (06) :820-827
[4]   Clades of Adeno-associated viruses are widely disseminated in human tissues [J].
Gao, GP ;
Vandenberghe, LH ;
Alvira, MR ;
Lu, Y ;
Calcedo, R ;
Zhou, XY ;
Wilson, JA .
JOURNAL OF VIROLOGY, 2004, 78 (12) :6381-6388
[5]   New recombinant serotypes of AAV vectors [J].
Gao, GP ;
Vandenberghe, LH ;
Wilson, JM .
CURRENT GENE THERAPY, 2005, 5 (03) :285-297
[6]   Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy [J].
Gao, GP ;
Alvira, MR ;
Wang, LL ;
Calcedo, R ;
Johnston, J ;
Wilson, JM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (18) :11854-11859
[7]   Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids [J].
Grifman, M ;
Trepel, M ;
Speece, P ;
Gilbert, LB ;
Arap, W ;
Pasqualini, R ;
Weitzman, MD .
MOLECULAR THERAPY, 2001, 3 (06) :964-975
[8]   Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6 [J].
Grimm, D ;
Kay, MA ;
Kleinschmidt, JA .
MOLECULAR THERAPY, 2003, 7 (06) :839-850
[9]   Novel tools for production and purification of recombinant adenoassociated virus vectors [J].
Grimm, D ;
Kern, A ;
Rittner, K ;
Kleinschmidt, JA .
HUMAN GENE THERAPY, 1998, 9 (18) :2745-2760
[10]  
Kalendar R., FASTPCR PCR PRIMER P